All Relations between glp-1 and insulin

Publication Sentence Publish Date Extraction Date Species
Lampros G Chrysavgis, Spyridon Kazanas, Konstantina Bafa, Sophia Rozani, Maria-Evangelia Koloutsou, Evangelos Cholongita. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. International journal of molecular sciences. vol 25. issue 7. 2024-04-13. PMID:38612640. glucagon-like peptide 1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are incretins that regulate postprandial glucose regulation, stimulating insulin secretion from pancreatic β-cells in response to food ingestion. 2024-04-13 2024-04-15 human
Junping Guo, Xinghua Chen, Cole Wang, Feng Ruan, Yunhe Xiong, Lijun Wang, Osama Abdel-Razek, Qinghe Meng, Rauf Shahbazov, Robert N Cooney, Guirong Wan. LIRAGLUTIDE ALLEVIATES ACUTE LUNG INJURY AND MORTALITY IN PNEUMONIA-INDUCED SEPSIS THROUGH REGULATING SURFACTANT PROTEIN EXPRESSION AND SECRETION. Shock (Augusta, Ga.). vol 61. issue 4. 2024-04-12. PMID:38150354. glucagon-like peptide 1 (glp-1) analogs are used to treat type 2 diabetes, and they can regulate insulin secretion, energy homeostasis, inflammation, and immune cell function. 2024-04-12 2024-04-14 mouse
H B Carslake, G L Pinchbeck, C M Argo, A H A Dugdale, C M McGowa. Investigation of glucagon-like peptide-1 response to six oral carbohydrates in ponies. Veterinary journal (London, England : 1997). 2024-04-11. PMID:38604332. glucagon-like peptide-1 (glp-1), the principal incretin in horses, may play a role in the pathophysiology of insulin dysregulation (id). 2024-04-11 2024-04-14 Not clear
H B Carslake, G L Pinchbeck, C M Argo, A H A Dugdale, C M McGowa. Investigation of glucagon-like peptide-1 response to six oral carbohydrates in ponies. Veterinary journal (London, England : 1997). 2024-04-11. PMID:38604332. glucose, insulin and glp-1 concentrations were measured before and following each intervention. 2024-04-11 2024-04-14 Not clear
Zhenyu Liu, Huixi Kong, Baoyu Zhan. Narrative literature review of antidiabetic drugs' effect on hyperuricemia: elaborate on actual data and mechanisms. Endocrine connections. 2024-04-05. PMID:38579756. we find that insulin and dipeptidyl peptidase 4 inhibitor (dpp-4i) except linagliptin could increase the sua, and other drugs including metformin, thiazolidinediones (tzds), glucagon-like peptide-1 receptor agonists (glp-1 ras), linagliptin, sodium-glucose cotransporter 2 inhibitors (sglt2i) and α-glucosidase inhibitors have a reduction effect on sua. 2024-04-05 2024-04-10 Not clear
Svjatoslavs Kistkins, Othmar Moser, Vitālijs Ankudovičs, Dmitrijs Bliznuks, Timurs Mihailovs, Sergejs Lobanovs, Harald Sourij, Andreas F H Pfeiffer, Valdis Pirag. From classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and GLP-1 for the treatment of diabesity. Endocrine connections. 2024-04-05. PMID:38579770. from classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and glp-1 for the treatment of diabesity. 2024-04-05 2024-04-10 Not clear
Svjatoslavs Kistkins, Othmar Moser, Vitālijs Ankudovičs, Dmitrijs Bliznuks, Timurs Mihailovs, Sergejs Lobanovs, Harald Sourij, Andreas F H Pfeiffer, Valdis Pirag. From classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and GLP-1 for the treatment of diabesity. Endocrine connections. 2024-04-05. PMID:38579770. this review aims to provide insights into the cross-interactions of insulin, glucagon, and glp-1, revealing the complex hormonal dynamics during fasting and postprandial states, impacting glucose homeostasis, energy expenditure, and other metabolic functions. 2024-04-05 2024-04-10 Not clear
Samrin Kagdi, Sulayman Lyons, Jacqueline L Beaudr. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. The Journal of endocrinology. 2024-04-05. PMID:38579777. glucose-dependent insulinotropic polypeptide (gip) is an incretin hormone secreted from the small intestinal k-cells, responsible for augmenting insulin release, and has gained attention for its independent and amicable effects with glucagon-like peptide-1 (glp-1), another incretin hormone secreted from the small intestinal l-cells. 2024-04-05 2024-04-10 human
Samrin Kagdi, Sulayman Lyons, Jacqueline L Beaudr. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. The Journal of endocrinology. 2024-04-05. PMID:38579777. the gip receptor (gipr) is found in whole adipose tissue, whereas the glp-1 receptor (glp-1r) is not, and some studies suggest that gipr action lowers body weight and plays a role in lipolysis, glucose/lipid uptake/disposal, adipose tissue blood flow, lipid oxidation, and free-fatty acid (ffa) re-esterification that may or may not be influenced by other hormones such as insulin. 2024-04-05 2024-04-10 human
Janet B McGill, Irl B Hirsch, Christopher G Parkin, Grazia Aleppo, Carol J Levy, James R Gavi. The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2024-04-04. PMID:38573469. in this narrative review, we discuss current evidence that supports glp-1 ra use in combination with insulin therapy and the potential pitfalls of reliance on glp-1 ras as a substitute for insulin therapy. 2024-04-04 2024-04-06 Not clear
Elizabeth Van Dril, Margaret Allison, Christie Schumache. Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy. American heart journal plus : cardiology research and practice. vol 17. 2024-04-01. PMID:38559880. while the etiology of their underuse is multifactorial, lack of comfortability in adding a glp-1 receptor agonist to established insulin regimens is a common barrier. 2024-04-01 2024-04-04 Not clear
Elizabeth Van Dril, Margaret Allison, Christie Schumache. Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy. American heart journal plus : cardiology research and practice. vol 17. 2024-04-01. PMID:38559880. adjustments to basal and bolus insulin doses upon initiation of glp-1 receptor agonists in trials have varied. 2024-04-01 2024-04-04 Not clear
Elizabeth Van Dril, Margaret Allison, Christie Schumache. Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy. American heart journal plus : cardiology research and practice. vol 17. 2024-04-01. PMID:38559880. overall, initiation of glp-1 receptor agonists can decrease insulin requirements and may permit deintensification of antihyperglycemic therapy through the reduction or discontinuation of bolus insulin therapy. 2024-04-01 2024-04-04 Not clear
Elizabeth Van Dril, Margaret Allison, Christie Schumache. Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy. American heart journal plus : cardiology research and practice. vol 17. 2024-04-01. PMID:38559880. this review aims to serve as a guide for clinicians to facilitate the initiation of glp-1 receptor agonists and deintensification of insulin by providing suggested dose adjustments based on available literature. 2024-04-01 2024-04-04 Not clear
Masashi Iida, Atsushi Asan. Effects of glucagon-like peptide-1 receptor agonists on spermatogenesis-related gene expression in mouse testis and testis-derived cell lines. The Journal of veterinary medical science. 2024-03-31. PMID:38556323. glucagon-like peptide-1 (glp-1) is an incretin released into the gastrointestinal tract after food ingestion, and stimulates insulin secretion from the beta cells of the pancreatic islets. 2024-03-31 2024-04-03 mouse
Kayoko Kamemoto, Yusei Tataka, Ayano Hiratsu, Chihiro Nagayama, Yuka Hamada, Koji Kurata, Michiko Chiyoda, Machi Ito, Masashi Miyashit. Effect of vegetable consumption with chewing on postprandial glucose metabolism in healthy young men: a randomised controlled study. Scientific reports. vol 14. issue 1. 2024-03-30. PMID:38555375. circulating concentrations of glucose, insulin, total glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic peptide (gip) concentrations were measured from the plasma. 2024-03-30 2024-04-02 Not clear
Harunobu Nishizaki, Tomoya Kagawa, Jun Sugama, Akihiro Kobayashi, Yusuke Moritoh, Masanori Watanab. Oral SSTR5 Antagonist SCO-240 for Growth Hormone Stimulation: A Phase I Single-Dose Study in Healthy Individuals. Clinical pharmacology and therapeutics. 2024-03-29. PMID:38549435. the main outcome measures were safety, tolerability, pharmacokinetics, and pharmacodynamics (gallbladder contractions and levels of serum insulin and plasma glucagon-like peptide-1 (glp-1)). 2024-03-29 2024-03-31 Not clear
Harunobu Nishizaki, Tomoya Kagawa, Jun Sugama, Akihiro Kobayashi, Yusuke Moritoh, Masanori Watanab. Oral SSTR5 Antagonist SCO-240 for Growth Hormone Stimulation: A Phase I Single-Dose Study in Healthy Individuals. Clinical pharmacology and therapeutics. 2024-03-29. PMID:38549435. no increase in gallbladder contractions or levels of insulin and glp-1 were detected. 2024-03-29 2024-03-31 Not clear
Jens Juul Holst, Sten Madsbad, Kirstine Nyvold Bojsen-Møller, Carsten Dirksen, Maria Svan. New Lessons from the gut: studies of the role of gut peptides in weight loss and diabetes resolution after gastric bypass and sleeve gastrectomy. Peptides. 2024-03-29. PMID:38552903. it seems clear that changes in glp-1 secretion are important for insulin secretion after bypass and appear to be responsible for postbariatric hypoglycemia in glucose-tolerant individuals; however, with time the improvements in insulin sensitivity, which in turn are secondary to the weight loss, may be more important. 2024-03-29 2024-04-01 Not clear
Cheol-Won Jang, Tae Yang Yu, Jin Woo Jeong, Se Eun Ha, Rajan Singh, Moon Young Lee, Seungil R. Fasting GLP-1 Levels and Albuminuria Are Negatively Associated in Patients with Type 2 Diabetes Mellitus. Journal of personalized medicine. vol 14. issue 3. 2024-03-28. PMID:38541022. glucagon-like peptide-1 (glp-1) is an incretin hormone known for its pivotal role in enhancing insulin secretion and reducing glucagon release from the pancreas. 2024-03-28 2024-03-30 human